Multi-targeted tyrosine kinase inhibitor

This page covers all Multi-targeted tyrosine kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGFR, PDGFR, KIT, FLT3, VEGFR, FGFR, PDGFR, c-Kit, RET, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit.

Targets

VEGFR, PDGFR, KIT, FLT3 · VEGFR, FGFR, PDGFR, c-Kit, RET · VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit · VEGFR, FGFR, and other receptor tyrosine kinases · MET, VEGFR2, AXL · VEGFR (VEGF receptor), PDGFR, and other receptor tyrosine kinases · MET, VEGFR2, RET · FGFR1-4, VEGFR1-3, RET, KIT, PDGFR-alpha · FGFR, VEGFR, and other receptor tyrosine kinases · VEGFR2, FGFR1, PDGFR-β, c-Kit, Ret

Marketed (4)

• Sunitinib Malate (SU011248) · H. Lee Moffitt Cancer Center and Research Institute · Oncology
  Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation.
• Anlotinib hydrochloride capsules · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
  Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.
• Sunitinib (Sutent) · Sponsor GmbH · Oncology
  Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation.
• pazopanib or guideline conform chemotherapy · GWT-TUD GmbH · Oncology
  Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling.

Phase 3 pipeline (9)

• TT-00420 (tinengotinib) · TransThera Sciences (Nanjing), Inc. · Oncology
  Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
• Cabozantinib tablets · Exelixis · Oncology
  Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis.
• AG-013736 · University of Wisconsin, Madison · Oncology
  AG-013736 is a tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in angiogenesis and tumor growth.
• XL184 · Exelixis · Oncology
  XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis.
• Lenvatinib Capsules · National Cancer Institute, Naples · Oncology
  Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth.
• AL3818 Capsule · Advenchen Laboratories Nanjing Ltd. · Oncology
  AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
• Anlotinib(blank) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
  Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.
• Concurrent Lenvatinib · Sun Yat-sen University · Oncology
  Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling to inhibit tumor angiogenesis and growth.
• Placebo matching lenvatinib · Merck Sharp & Dohme LLC · Oncology
  Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks signaling pathways critical for tumor growth and angiogenesis.